The first quarter of 2023 saw just £295 million raised by UK-based life sciences and biotech companies, signalling that investor confidence remains low after a disappointi
The UK’s voluntary system of revenue rebates to limit rises in medicines spending is already causing deep upset among branded drug manufacturers as clawbacks rise.
The 2019 Voluntary Scheme for Branded Medicines Access and Pricing (VPAS) saw the industry agreeing to make payments to the Department of Health and Social Care (DHSC).
US biotech Moderna has chosen the location of its promised new R&D facility in the UK, selecting the Harwell Science Campus in Oxfordshire to site the unit.
The UK government’s decision to raise the revenue clawback rate in the Statutory Scheme for controlling the costs to the NHS for purchasing branded medicines has prompted
Drastic steps need to be taken if the UK is to reverse a steep decline in medicines manufacturing in recent years, according to a cross-industry coalition.
Bavarian Nordic is preparing to file for regulatory approval of a vaccine against chikungunya virus after its CHIKV VLP candidate showed protective efficacy in a second ph
To improve trial recruitment, engagement, and retention, and to increase the likelihood that trials reflect what matters most to patients, regulatory authorities increasingly point to metho